Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the ...
The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...
Approximately 25-30% of lung cancer patients lack mutations targeted by current therapies, necessitating novel approaches. New targets, including MTAP deletions, SMARC4, and p53 mutations, show ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
Researchers have uncovered a mechanism that allows breast cancer to send metastases to the brain, potentially enabling the ...
The safety population consisted of 109 patients treated with at least one dose of rezatapopt 2000 mg daily as monotherapy. Median number of prior lines of systemic therapy was three (range: 1-10) The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback